Thermo Fisher closes Henogen acquisition

By The Science Advisory Board staff writers

January 15, 2021 -- Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million euros ($876 million U.S.) in cash.

The business provides contract manufacturing services for vaccines and therapies to biotechnology companies as well as large biopharma customers. Henogen has two locations in Seneffe and Gosselies, Belgium, with approximately 400 employees. The 2020 estimated revenues were 80 million euros ($95 million).

Henogen will become part of Thermo Fisher Scientific's Pharma Services business within its Laboratory Products and Services Segment.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.